Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Trading 11-22 12:11:12 EST

0.8645

+0.0928

+12.03%

High0.8700	Low0.7300	Vol6.30M
Open0.7430	D1 Closing0.7717	Amplitude18.14%
Mkt Cap312.51M	Tradable Cap157.46M	Total Shares361.49M
T/O5.04M	T/O Rate3.46%	Tradable Shares182.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":0.8645,"timestamp":1732295462762,"preClose":0.7717,"halted":0,"volume":6298773,"delay":0,"floatShares":182142700,"shares":361492295,"eps":-0.743931,"marketStatus":"Trading","change":0.0928,"latestTime":"11-22 12:11:12 EST","open":0.743,"high":0.87,"low":0.73,"amount":5044760.73939318,"amplitude":0.181418,"askPrice":0.8673,"askSize":400,"bidPrice":0.8621,"bidSize":179,"shortable":3,"etf":0,"ttmEps":-0.743931,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":0.7717,"preHourTrading":{"tag":"盘前","latestPrice":0.75,"preClose":0.7717,"latestTime":"09:25 EST","volume":513856,"amount":368347.8589504,"timestamp":1732285500183},"postHourTrading":{"tag":"盘后","latestPrice":0.77,"preClose":0.7717,"latestTime":"19:53 EST","volume":67879,"amount":52610.9046,"timestamp":1732236832295},"volumeRatio":4.174619,"impliedVol":0.8981,"impliedVolPercentile":0.4127},"requestUrl":"/m/hq/s/LXRX/tweets","defaultTab":"tweets","newsList":[{"id":"2485952252","title":"HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2485952252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485952252?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:45","pubTimestamp":1732293908,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) has an average rating of overweight and mean price target of $4.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXRX"],"gpt_icon":0},{"id":"2485956432","title":"BUZZ-Lexicon Pharmaceuticals rises on plan to lay off 60% of employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2485956432","media":"Reuters","labels":["Shareholding Changes","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485956432?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:38","pubTimestamp":1732293520,"startTime":"0","endTime":"0","summary":"BUZZ-Lexicon Pharmaceuticals rises on plan to lay off 60% of employees** Lexicon Pharmaceuticals' LXRX.O shares rise 6.3% to 82 cents** Co says it plans to cut about 60% of its workforce effective Dec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4N3MT10N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Shareholding Changes,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485295111","title":"Lexicon price target lowered to $4 from $6 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2485295111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485295111?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:30","pubTimestamp":1732293031,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Lexicon (LXRX) to $4 from $6 and keeps a Buy rating on the shares. The company announced that fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-lowered-to-4-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-lowered-to-4-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485932772","title":"Lexicon Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $4 From $6","url":"https://stock-news.laohu8.com/highlight/detail?id=2485932772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485932772?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:28","pubTimestamp":1732292890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nAZN2O2P0E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485826319","title":"Lexicon Pharmaceuticals to Cut 60% of Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2485826319","media":"MT Newswires Live","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485826319?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:43","pubTimestamp":1732283026,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) said Friday it plans to cut 60% of its workforce, with most departures effective by Dec. 31, as part of a shift to focus on its clinical development pipeline.The company","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485250921","title":"UPDATE 1-Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250921?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:11","pubTimestamp":1732281118,"startTime":"0","endTime":"0","summary":"(Adds details throughout)      Nov 22 (Reuters) - Lexicon Pharmaceuticals    said on Friday it would reduce its workforce by about 60%, after the U.S. Food and Drug Administration noted deficiencies i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485539250","title":"Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization","url":"https://stock-news.laohu8.com/highlight/detail?id=2485539250","media":"Dow Jones","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485539250?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:04","pubTimestamp":1732280640,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals said that it will lay off 60% of its staff and eliminate its commercial operations as part of a broader restructuring effort.The biopharmaceutical company said Friday that the decisions are part of an effort to preserve its cash and focus its resources on advancing its clinical development pipeline.\"This prioritization of investment is designed to advance the research and development programs that have the greatest potential for value creation and patient impact,\" the company said.Recently, Lexicon received a \"deficiencies preclude discussion\" letter from the Food and Drug Administration regarding a new drug application for its insulin therapy Zynquista, or Sotagliflozin, which precluded discussion of labeling and post-marketing requirements and commitments.The restructuring will eliminate its commercial field team and reduce the size of other functions across the business, including promotional activity for its other drugs, Inpefa and Zynquista.It will also eli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485508702","title":"Lexicon falls on restructuring program","url":"https://stock-news.laohu8.com/highlight/detail?id=2485508702","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485508702?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:02","pubTimestamp":1732280559,"startTime":"0","endTime":"0","summary":"cagkansayin Lexicon Pharmaceuticals  lost ~11% in the premarket on Friday after announcing plans to eliminate its commercial operations in a bid to generate as much as $100M in cost savings next year. The decision follows the FDA’s rejection of the company’s New Drug Application  for diabetes therapy, Zynquista , based on deficiencies found in the NDA.  Accordingly, Lexicon’s  commercial field team will be axed, and 60% of the company’s workforce will lose their jobs. The size of the company’s other functions will also be reduced, and all ongoing and planned promotional efforts for its commercialized drugs, Inpefa and Zynquista, will also come to an end. Through the program, Lexicon  plans to cut its 2025 operating costs by $100M.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164034397/image_2164034397.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164034397/image_2164034397.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4320853-lexicon-stock-falls-restructuring-program","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["NQmain","TQQQ","LXRX","SQQQ","MNQmain","QID","QLD",".IXIC","BK4139","PSQ"],"gpt_icon":1},{"id":"2485524152","title":"Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development","url":"https://stock-news.laohu8.com/highlight/detail?id=2485524152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485524152?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:43","pubTimestamp":1732279422,"startTime":"0","endTime":"0","summary":"Nov 22 (Reuters) - Lexicon Pharmaceuticals    said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development. (Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)((Mariam.ESunny@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485252197","title":"Lexicon to eliminate commercial organization, focus on clinical development","url":"https://stock-news.laohu8.com/highlight/detail?id=2485252197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485252197?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:40","pubTimestamp":1732279224,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) Pharmaceuticals announced that the company has made the strategic decision to eliminate its commercial operations and rationalize re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-to-eliminate-commercial-organization-focus-on-clinical-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-to-eliminate-commercial-organization-focus-on-clinical-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485252504","title":"BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2485252504","media":"Reuters","labels":["Policy And Regulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485252504?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:36","pubTimestamp":1732278999,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDANov 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON TO REPOSITION AS CLINICAL DEVELOPM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485925471","title":"Lexicon Pharmaceuticals Inc: Prioritizing Strong R&D Pipeline Including Ongoing Studies in Dpnp, HCM and Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2485925471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485925471?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:32","pubTimestamp":1732278742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485716254","title":"Lexicon Pharmaceuticals Inc: Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions","url":"https://stock-news.laohu8.com/highlight/detail?id=2485716254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485716254?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:32","pubTimestamp":1732278742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485547972","title":"Lexicon Pharmaceuticals Inc: Total Reduction of Approximately 60 Percent of Employees, Effective for Most Affected Employees by December 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2485547972","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485547972?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:32","pubTimestamp":1732278742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485547132","title":"Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2485547132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485547132?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:32","pubTimestamp":1732278742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485254770","title":"Lexicon Pharmaceuticals Inc:  Elimination of Promotional Efforts for Inpefa, Planned Commercial Activities for Zynquista","url":"https://stock-news.laohu8.com/highlight/detail?id=2485254770","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485254770?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:32","pubTimestamp":1732278742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139"],"gpt_icon":0},{"id":"2485254718","title":"Lexicon Pharmaceuticals Inc: Efforts Expected to Reduce 2025 Operating Costs by $100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2485254718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485254718?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:32","pubTimestamp":1732278742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485252503","title":"Lexicon Pharmaceuticals Inc:  Receipt of a \"Deficiencies Preclude Discussion\" Letter From FDA Regarding Nda for Zynquista","url":"https://stock-news.laohu8.com/highlight/detail?id=2485252503","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485252503?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:32","pubTimestamp":1732278742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485179313","title":"Lexicon Pharmaceuticals Appoints Ivan Cheung to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2485179313","media":"TIPRANKS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485179313?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:33","pubTimestamp":1732138430,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals ( ($LXRX) ) has shared an update. Lexicon Pharmaceuticals has appointed Ivan H. Cheung, a seasoned executive with extensive...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-appoints-ivan-cheung-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-appoints-ivan-cheung-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2485173547","title":"Lexicon Appoints Ivan H. Cheung to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2485173547","media":"THOMSON REUTERS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485173547?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:05","pubTimestamp":1732136747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA6M0XHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.272},{"period":"1month","weight":-0.6022},{"period":"3month","weight":-0.5783},{"period":"6month","weight":-0.5236},{"period":"1year","weight":-0.2985},{"period":"ytd","weight":-0.4956}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.042931},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.058519},{"month":3,"riseRate":0.5,"avgChangeRate":-0.006016},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.011119},{"month":5,"riseRate":0.52,"avgChangeRate":0.035958},{"month":6,"riseRate":0.64,"avgChangeRate":0.119795},{"month":7,"riseRate":0.48,"avgChangeRate":0.017089},{"month":8,"riseRate":0.24,"avgChangeRate":-0.027412},{"month":9,"riseRate":0.32,"avgChangeRate":0.002483},{"month":10,"riseRate":0.52,"avgChangeRate":-0.007629},{"month":11,"riseRate":0.36,"avgChangeRate":-0.045597},{"month":12,"riseRate":0.5,"avgChangeRate":0.078876}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction